triple-negative-breast-cancer

Documents about triple-negative-breast-cancer

• Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy#1010240ClinicalTrials.gov
• A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients#805598ClinicalTrials.gov
• Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer#893611ClinicalTrials.gov
• ARGONAUT: Stool and Blood Sample Bank for Cancer Patients#121332ClinicalTrials.gov
• Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy#863935ClinicalTrials.gov
• A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)#849721ClinicalTrials.gov
• Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer#366590ClinicalTrials.gov
• Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer#843342ClinicalTrials.gov
• Clinical, pathological, treatment, and follow-up data of patients with triple-negative breast cancer treated with carboplatin-containing neoadjuvant chemotherapy#443363Repositório de Dados de Pesquisa da Unicamp Dataverse OAI Archive
• A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)#827663ClinicalTrials.gov
• A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer#160354ClinicalTrials.gov
• Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab#801694ClinicalTrials.gov
• PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC#460075ClinicalTrials.gov
• Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR#121862HAL (France)
• Biomarker identification of triple negative breast cancer subtypes using machine learning.#342502NCBI PubMed Central
• Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer#877323ClinicalTrials.gov
• A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer#855003ClinicalTrials.gov
• 2'-Nitroflavone targets PARP1 and alters cytoskeleton to inhibit triple-negative breast cancer progression#365264Repositorio Institucional UCA
• Personalized Vaccine for Cancer Immunotherapy#836574ClinicalTrials.gov
• Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy#813411ClinicalTrials.gov
• <i>TP53</i>#448598Figshare
• Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer#981016ClinicalTrials.gov
• PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer#432895ClinicalTrials.gov
• Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy#390915ClinicalTrials.gov
• Feasibility of a Lifestyle Intervention for Women With Triple-negative Breast Cancer Under Neoadjuvant Immunotherapy#154643ClinicalTrials.gov
• Artificial intelligence for triple-negative breast cancer from imaging to multi-omics.#371435NCBI PubMed Central
• Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency#842302ClinicalTrials.gov
• Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer#911502ClinicalTrials.gov
• Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC#300261ClinicalTrials.gov
• Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast Cancer#28295ClinicalTrials.gov
• Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer#802048ClinicalTrials.gov
• Investigating the anticancer potential of phytocompounds isolated from Clinacanthus nutans, as monotherapy and in combination with cisplatin, against triple-negative breast cancer (MDA-MB-231)#447203University of Nottingham Repository
• Development of predictive models for the prognosis of triple-negative breast cancer using multiple transcriptomic analyses#152679PLOS
• Lavandula stoechas ethanol extracts induce apoptosis in breast, bladder, and glioblastoma cancer cells#351957Recep Tayyip Erdoğan University Institutional Repository
• Subtype-Specific Divergent Roles of Calpain-1 and Calpain-2 in Basal a Triple-Negative Breast Cancer#1027113İzmir Yüksek Teknoloji Enstitüsü
• Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients#130989ClinicalTrials.gov
• Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer#183837Ora Oxford University Research
• CDK4 inactivation inhibits apoptosis via mitochondria-ER contact remodeling in triple-negative breast cancer#262017HAL (France)
• Stage-specific biomarkers in triple-negative breast cancer: Preliminary findings from bioinformatics approaches.#305140NCBI PubMed Central
• CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells#350693HAL (France)
• NMR spectroscopy stability studies of Ru-IM, a prodrug candidate for triple negative breast cancer#922950HAL (France)
• Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry#806175ClinicalTrials.gov
• Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC#858150ClinicalTrials.gov
• A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors#879824ClinicalTrials.gov
• Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted#812914ClinicalTrials.gov
• ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer#916096ClinicalTrials.gov
• AZD8186 First Time In Patient Ascending Dose Study#840433ClinicalTrials.gov
• PRO1107 in Patients With Advanced Solid Tumors#852344ClinicalTrials.gov
• Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients With rCR and pCR in the Breast After NAST#803556ClinicalTrials.gov
• AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer#1031207ClinicalTrials.gov